Xencor Financial Ratios
NASDAQ: XNCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
24.63+0.13 (+0.53%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xencor ratio analysis
Xencor earned a net margin of -73.2% in FY 2025, up from -210.5% a year earlier. Return on equity reached -14.5%, meaning Xencor generated -0.14 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.19 versus 0.24 the year before, and the current ratio was 6.25.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Xencor financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | — | 29.28 | — | 75.78 | — | — | 24.60 |
| Price / sales | 8.82 | 14.20 | 7.36 | 9.44 | 8.51 | 20.34 | 12.58 | 48.60 | 22.24 | 9.96 |
| Price / book | 1.74 | 2.32 | 1.94 | 2.14 | 3.19 | 4.36 | 3.32 | 3.78 | 3.24 | 3.21 |
| Operating margin | -141.4% | -161.5% | -75.8% | -50.1% | 15.9% | -62.6% | 8.8% | -195.5% | -93.4% | 40.4% |
| Net margin | -73.2% | -210.5% | -76.2% | -33.5% | 30.0% | -56.5% | 17.2% | -173.4% | -83.4% | 41.4% |
| Free cash flow margin | -110.1% | -188.5% | -55.2% | -8.5% | -11.0% | -12.7% | 36.4% | -214.2% | -84.3% | 86.0% |
| Return on equity (ROE) | -14.5% | -34.3% | -20.1% | -7.6% | 11.3% | -12.1% | 4.5% | -13.5% | -12.2% | 13.4% |
| Return on assets (ROA) | -10.5% | -24.4% | -13.8% | -6.5% | 9.9% | -9.9% | 4.0% | -12.2% | -9.9% | 10.5% |
| Debt / equity | 0.19 | 0.24 | 0.29 | 0.00 | — | — | — | — | — | — |
| Current ratio | 6.25 | 6.61 | 8.60 | 10.58 | 6.00 | 5.27 | 8.39 | 5.86 | 3.18 | 1.33 |
| Revenue growth | 13.7% | -36.7% | 6.1% | -40.2% | 124.2% | -21.7% | 285.9% | -12.0% | -57.7% | — |
| EPS growth | — | — | — | -167.9% | — | -363.0% | — | — | -176.6% | — |